Client Result

Oncology Diagnostics Landscape Assessment and Model

Project Overview

DeciBio performed a global voice-of-customer (VOC) research campaign with oncologists and pathologists to understand the current adoption and expected trends for NGS kits in oncology diagnostics in the U.S., EU, and APAC.

DeciBio Approach

Primary Research

  • Conducted 32 in-depth interviews with oncologists, pathologists, and lab directors to better understand current and future use, as well as trends for NGS tissue testing and liquid biopsy
  • Interviews spanned the U.S., EU, and APAC and across various institution types such as reference labs / CROs, community hospitals, and academic medical centers

Quantitative Analyses

Developed a comprehensive model of the current and future (5-year forecast) oncology diagnostics market, including segmentation by:

  • Geography: U.S., Europe, APAC
  • Cancer type: Lung cancer, breast cancer, colorectal cancer, others
  • Sample type: Tissue, liquid
  • Application: Therapy selection, MRD (solid tumors), surveillance / monitoring
  • Setting: Academic hospital lab, community hospital lab, commercial reference lab
At a glance
Countries Covered
Model segmentations

DeciBio delivered a summary report and detailed model outlining:

  • Current use of genomic biomarker assays across regions
  • NGS use and liquid biopsy use in routine clinical care
  • Trends and factors affecting centralization of genomic testing, as well as panel size preferences
  • Trends and factors in regulatory implementation / compliance and IVD use
  • Country-specific reimbursement models and drivers and moderators of oncology NGS testing

8 weeks

Geographic Scope



Clinical Diagnostics


Voice-Of-Customer Research

Biomarker and Diagnostic Strategy

Addressable Market Sizing

Related Client Results

Precision Medicine is evolving at a rapid pace

Discover how we can help

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.